Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

@article{Raffi2013OncedailyDV,
  title={Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.},
  author={François Raffi and Hans Jaeger and Eugenia Quir{\'o}s-Rold{\'a}n and Helmut Albrecht and Elena Belonosova and Jose M. Gatell and J G Baril and Pere Domingo and Clare Brennan and Steve Almond and Sherene Min},
  journal={The Lancet. Infectious diseases},
  year={2013},
  volume={13 11},
  pages={927-35}
}
BACKGROUND In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. METHODS SPRING-2 is an ongoing phase 3, randomised, double-blind, active-controlled, non-inferiority study in treatment-naive adults infected with HIV-1 that started in Oct 19, 2010. We present results for the safety cutoff date of Jan 30, 2013… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 102 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Meta - analysis of gender diff erences in effi cacy outcomes for HIV - positive subjects in randomized controlled clinical trials of antiretroviral therapy ( 2000 – 2008 )

  • S Walmsley, A Antela, N Clumeck
  • AIDS Patient Care STDS
  • 2012

Abstract A1-1724

  • GG Soon, M Min, KA Struble
  • ux transporters. 51st Interscience Conference on…
  • 2011

Similar Papers

Loading similar papers…